Defining the role of cancer-risk genes in Type 2 diabetes pathogenesis

Completed

• Conditions: dragers van een p16-gen mutatie; diabetes mellitus; 10018424

• Registration Number: NL-OMON36169
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

carrier of a CDKN2A (p16) mutation and partners or relatives without a CDKN2A-mutation

Exclusion Criteria

Being unwell or unable to give informed consent. Patients with dabetes mellitus

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Do people with mutations in certain cancer*risk genes (CDKN2A) have altered<br /><br>glucose tolerance.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>not applicable</p><br>